Published in Lancet Oncol on October 01, 2009
Knowledge of human papillomavirus infection and its prevention among adolescents and parents in the greater Milan area, Northern Italy. BMC Public Health (2010) 1.03
Human papillomaviruses as therapeutic targets in human cancer. J Clin Oncol (2011) 0.90
HPV16-E7 expression in squamous epithelium creates a local immune suppressive environment via CCL2- and CCL5- mediated recruitment of mast cells. PLoS Pathog (2014) 0.88
Combined treatment of the experimental human papilloma virus-16-positive cervical and head and neck cancers with cisplatin and radioimmunotherapy targeting viral E6 oncoprotein. Br J Cancer (2013) 0.87
Monitoring of human papillomavirus vaccination. Clin Exp Immunol (2010) 0.86
HPV in oropharyngeal cancer: the basics to know in clinical practice. Acta Otorhinolaryngol Ital (2014) 0.85
Randomized clinical trial of imiquimod: an adjunct to treating cervical dysplasia. Am J Obstet Gynecol (2011) 0.82
Human papillomavirus e7 oncoprotein transgenic skin develops an enhanced inflammatory response to 2,4-dinitrochlorobenzene by an arginase-1-dependent mechanism. J Invest Dermatol (2014) 0.81
Dendritic cells and vaccine design for sexually-transmitted diseases. Microb Pathog (2012) 0.80
Long-peptide therapeutic vaccination against CRPV-induced papillomas in HLA-A2.1 transgenic rabbits. Trials Vaccinol (2014) 0.76
Do selective estrogen receptor modulators treat cervical precancer and cancer? Time to pool data from relevant trials. Int J Cancer (2011) 0.76
Interferon α Induces the Apoptosis of Cervical Cancer HeLa Cells by Activating both the Intrinsic Mitochondrial Pathway and Endoplasmic Reticulum Stress-Induced Pathway. Int J Mol Sci (2016) 0.76
Non-responders to topical imiquimod followed by vaccination therapy in VIN patients may be due to the level of IL10. Br J Cancer (2010) 0.75
Koch Institute Symposium on Cancer Immunology and Immunotherapy. Cancer Immunol Res (2013) 0.75
Blocking IL-10 signalling at the time of immunization does not increase unwanted side effects in mice. BMC Immunol (2017) 0.75
The global health burden of infection-associated cancers in the year 2002. Int J Cancer (2006) 13.57
Treatment of vulvar intraepithelial neoplasia with topical imiquimod. N Engl J Med (2008) 4.33
Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine (2008) 4.31
CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained. Eur J Immunol (2000) 3.36
Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis (2000) 3.36
Epidemiology of genital human papillomavirus infection. Epidemiol Rev (1988) 3.32
Immortalization and altered differentiation of human keratinocytes in vitro by the E6 and E7 open reading frames of human papillomavirus type 18. J Virol (1990) 3.29
Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine (2006) 2.78
A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet (1996) 2.59
Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol (1998) 2.37
Dissection of human papillomavirus E6 and E7 function in transgenic mouse models of cervical carcinogenesis. Cancer Res (2003) 2.32
Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype. Clin Cancer Res (2005) 2.21
Is the assumed natural history of vulvar intraepithelial neoplasia III based on enough evidence? A systematic review of 3322 published patients. Gynecol Oncol (2005) 1.93
Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis? J Pathol (2007) 1.93
Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst (2003) 1.84
Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol (2004) 1.81
A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin Cancer Res (2009) 1.79
Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: influence of the menstrual cycle. J Immunol (2002) 1.76
Antibodies against the human papillomavirus type 16 early proteins in human sera: correlation of anti-E7 reactivity with cervical cancer. J Natl Cancer Inst (1989) 1.72
Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res (2008) 1.66
Interaction of human papillomaviruses with the host immune system: a well evolved relationship. Virology (2008) 1.62
Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur J Cancer (1999) 1.44
Physical state and expression of HPV DNA in benign and dysplastic cervical tissue: different levels of viral integration are correlated with lesion grade. Gynecol Oncol (2004) 1.40
Viral DNA load, physical status and E2/E6 ratio as markers to grade HPV16 positive women for high-grade cervical lesions. Gynecol Oncol (2007) 1.37
A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res (2000) 1.32
Time to clearance of human papillomavirus infection by type and human immunodeficiency virus serostatus. Int J Cancer (2006) 1.28
Impaired antigen presentation and effectiveness of combined active/passive immunotherapy for epithelial tumors. J Natl Cancer Inst (2004) 1.28
Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine (2002) 1.25
Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes. Int J Cancer (2001) 1.25
Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res (2003) 1.24
HPV and cervical cancer in the 2007 report. Vaccine (2007) 1.23
ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol (2004) 1.22
Bovine papillomaviral gene expression in equine sarcoid tumours. Virus Res (1999) 1.19
Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide. Cancer Epidemiol Biomarkers Prev (2002) 1.19
Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope. Cancer Res (1996) 1.18
Presentation of the HPV16E7 protein by skin grafts is insufficient to allow graft rejection in an E7-primed animal. Virology (1997) 1.16
Cell-mediated immune responses to COPV early proteins. Virology (2006) 1.15
Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. Clin Cancer Res (2002) 1.15
Highly active antiretroviral therapy enhances regression of cervical intraepithelial neoplasia in HIV-seropositive women. AIDS (2002) 1.14
Dominance of virus-specific CD8 T cells in human primary cytomegalovirus infection. J Am Soc Nephrol (2002) 1.14
Use of fluorogenic histocompatibility leukocyte antigen-A*0201/HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-lymphocyte-recognizing endogenous human papillomavirus antigens. Cancer Res (2000) 1.14
Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia. J Natl Cancer Inst (1997) 1.13
Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6. J Immunol (2001) 1.13
Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. Clin Cancer Res (2003) 1.12
Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia. Vaccine (2004) 1.12
HPV6b virus like particles are potent immunogens without adjuvant in man. Vaccine (2000) 1.11
Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients. J Cancer Res Clin Oncol (2003) 1.10
Prevention of cancer through immunization: Prospects and challenges for the 21st century. Eur J Immunol (2007) 1.08
Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions. Int J Cancer (2008) 1.06
Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA. Am J Obstet Gynecol (2003) 1.05
Detection of human papillomavirus type 18 E6 and E7-specific CD4+ T-helper 1 immunity in relation to health versus disease. Int J Cancer (2006) 1.05
Clinical and immunologic results of a phase II trial of sequential imiquimod and photodynamic therapy for vulval intraepithelial neoplasia. Clin Cancer Res (2008) 1.05
Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3). Int J Cancer (2007) 1.04
Differential T helper cell responses to human papillomavirus type 16 E7 related to viral clearance or persistence in patients with cervical neoplasia: a longitudinal study. Cancer Res (1998) 1.04
Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia. Int J Cancer (2000) 1.02
Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia grade III. Cancer Res (1997) 0.99
The physical state of HPV16 infection and its clinical significance in cancer precursor lesion and cervical carcinoma. J Cancer Res Clin Oncol (2008) 0.98
Split tolerance to a viral antigen expressed in thymic epithelium and keratinocytes. Eur J Immunol (1998) 0.97
Multiple mechanisms underlie HLA dysregulation in cervical cancer. Tissue Antigens (2000) 0.93
Immunity to oncogenic human papillomaviruses. Adv Cancer Res (2001) 0.89
Activity of HspE7, a novel immunotherapy, in patients with anogenital warts. Dis Colon Rectum (2002) 0.87
TLR7 stimulation augments T effector-mediated rejection of skin expressing neo-self antigen in keratinocytes. Eur J Immunol (2008) 0.84
Therapeutic vaccination of rabbits with a ubiquitin-fused papillomavirus E1, E2, E6 and E7 DNA vaccine. Vaccine (2007) 0.84
Duration of anal human papillomavirus infection among immunocompetent women: clues to anal cancer epidemiology and possible prevention strategies. Clin Infect Dis (2009) 0.76
New gene functions in megakaryopoiesis and platelet formation. Nature (2011) 3.14
Common variants in TMPRSS6 are associated with iron status and erythrocyte volume. Nat Genet (2009) 2.29
Invariant NKT cells in hyperplastic skin induce a local immune suppressive environment by IFN-gamma production. J Immunol (2009) 1.81
Improving the reach of vaccines to low-resource regions, with a needle-free vaccine delivery device and long-term thermostabilization. J Control Release (2011) 1.77
Dry-coated microprojection array patches for targeted delivery of immunotherapeutics to the skin. J Control Release (2009) 1.71
Quantitative trait loci for CD4:CD8 lymphocyte ratio are associated with risk of type 1 diabetes and HIV-1 immune control. Am J Hum Genet (2009) 1.51
Antigen-specific CD4+ T-cell help is required to activate a memory CD8+ T cell to a fully functional tumor killer cell. Cancer Res (2002) 1.30
Impaired antigen presentation and effectiveness of combined active/passive immunotherapy for epithelial tumors. J Natl Cancer Inst (2004) 1.28
Sequence variants in three loci influence monocyte counts and erythrocyte volume. Am J Hum Genet (2009) 1.28
Potent immunity to low doses of influenza vaccine by probabilistic guided micro-targeted skin delivery in a mouse model. PLoS One (2010) 1.27
Nanopatch-targeted skin vaccination against West Nile Virus and Chikungunya virus in mice. Small (2010) 1.16
HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood. Vaccine (2005) 1.14
Chimeric human papilloma virus-simian/human immunodeficiency virus virus-like-particle vaccines: immunogenicity and protective efficacy in macaques. Virology (2002) 1.12
Inhibition of early tumor growth requires J alpha 18-positive (natural killer T) cells. Cancer Res (2003) 1.09
Codon usage bias and A+T content variation in human papillomavirus genomes. Virus Res (2003) 1.07
Codon modified human papillomavirus type 16 E7 DNA vaccine enhances cytotoxic T-lymphocyte induction and anti-tumour activity. Virology (2002) 1.06
Regulation of immune responses to HPV infection and during HPV-directed immunotherapy. Immunol Rev (2011) 1.05
IL10 and IL12B polymorphisms each influence IL-12p70 secretion by dendritic cells in response to LPS. Immunol Cell Biol (2006) 1.05
Gene codon composition determines differentiation-dependent expression of a viral capsid gene in keratinocytes in vitro and in vivo. Mol Cell Biol (2005) 1.03
Chapter 16: Prophylactic human papillomavirus vaccines. J Natl Cancer Inst Monogr (2003) 1.02
Skin vaccination against cervical cancer associated human papillomavirus with a novel micro-projection array in a mouse model. PLoS One (2010) 1.02
Despite differences between dendritic cells and Langerhans cells in the mechanism of papillomavirus-like particle antigen uptake, both cells cross-prime T cells. Virology (2004) 0.99
Replication of bovine papillomavirus type 1 (BPV-1) DNA in Saccharomyces cerevisiae following infection with BPV-1 virions. J Virol (2002) 0.97
Secretion of IFN-gamma but not IL-17 by CD1d-restricted NKT cells enhances rejection of skin grafts expressing epithelial cell-derived antigen. J Immunol (2010) 0.96
NKT cells inhibit antigen-specific effector CD8 T cell induction to skin viral proteins. J Immunol (2011) 0.94
Activation of dendritic cells by human papillomavirus-like particles through TLR4 and NF-kappaB-mediated signalling, moderated by TGF-beta. Immunol Cell Biol (2005) 0.93
Paucity of functional CTL epitopes in the E7 oncoprotein of cervical cancer associated human papillomavirus type 16. Immunol Cell Biol (2003) 0.93
Nanopatch targeted delivery of both antigen and adjuvant to skin synergistically drives enhanced antibody responses. J Control Release (2012) 0.92
Prevalence of cervical human papillomavirus (HPV) infection in Vanuatu. Cancer Prev Res (Phila) (2012) 0.92
Indoleamine 2,3-dioxygenase activity contributes to local immune suppression in the skin expressing human papillomavirus oncoprotein e7. J Invest Dermatol (2013) 0.92
Saccharomyces cerevisiae is permissive for replication of bovine papillomavirus type 1. J Virol (2002) 0.91
Multivariate QTL linkage analysis suggests a QTL for platelet count on chromosome 19q. Eur J Hum Genet (2004) 0.91
IFN-gamma promotes generation of IL-10 secreting CD4+ T cells that suppress generation of CD8 responses in an antigen-experienced host. J Immunol (2009) 0.90
Epithelial expression of human papillomavirus type 16 E7 protein results in peripheral CD8 T-cell suppression mediated by CD4+CD25+ T cells. Eur J Immunol (2009) 0.90
Overcoming original antigenic sin to generate new CD8 T cell IFN-gamma responses in an antigen-experienced host. J Immunol (2006) 0.90
Major quantitative trait locus for eosinophil count is located on chromosome 2q. J Allergy Clin Immunol (2004) 0.89
tRNASer(CGA) differentially regulates expression of wild-type and codon-modified papillomavirus L1 genes. Nucleic Acids Res (2004) 0.89
New Approaches to Immunotherapy for HPV Associated Cancers. Cancers (Basel) (2011) 0.89
Expression of a single, viral oncoprotein in skin epithelium is sufficient to recruit lymphocytes. PLoS One (2013) 0.89
Generalized substitution of isoencoding codons shortens the duration of papillomavirus L1 protein expression in transiently gene-transfected keratinocytes due to cell differentiation. Nucleic Acids Res (2007) 0.88
LPAR1 and ITGA4 regulate peripheral blood monocyte counts. Hum Mutat (2011) 0.87
Route of administration of chimeric BPV1 VLP determines the character of the induced immune responses. Immunol Cell Biol (2002) 0.86
ISCOMATRIX adjuvant: an adjuvant suitable for use in anticancer vaccines. Vaccine (2004) 0.86
A novel DNA vaccine technology conveying protection against a lethal herpes simplex viral challenge in mice. PLoS One (2013) 0.86
Effects of additional sequences directly downstream from the AUG on the expression of GFP gene. Biochim Biophys Acta (2003) 0.86
A combination of local inflammation and central memory T cells potentiates immunotherapy in the skin. J Immunol (2012) 0.85
Interferon-gamma enhances cytotoxic T lymphocyte recognition of endogenous peptide in keratinocytes without lowering the requirement for surface peptide. Immunol Cell Biol (2002) 0.84
TLR7 stimulation augments T effector-mediated rejection of skin expressing neo-self antigen in keratinocytes. Eur J Immunol (2008) 0.84
The number of long-lasting functional memory CD8+ T cells generated depends on the nature of the initial nonspecific stimulation. Eur J Immunol (2002) 0.83
Changes to peptide structure, not concentration, contribute to expansion of the lowest avidity cytotoxic T lymphocytes. J Leukoc Biol (2004) 0.83
Evaluation of a cervical cancer screening program based on HPV testing and LLETZ excision in a low resource setting. PLoS One (2010) 0.82
HPV vaccines: the beginning of the end for cervical cancer. Curr Opin Immunol (2007) 0.82
Increasing mechanical stimulus induces migration of Langerhans cells and impairs the immune response to intracutaneously delivered antigen. Exp Dermatol (2011) 0.82
IL-10 mediates suppression of the CD8 T cell IFN-gamma response to a novel viral epitope in a primed host. J Immunol (2003) 0.82
Calcium enhances mouse keratinocyte differentiation in vitro to differentially regulate expression of papillomavirus authentic and codon modified L1 genes. Virology (2007) 0.82
Antigen-specific CD4 cells assist CD8 T-effector cells in eliminating keratinocytes. J Invest Dermatol (2010) 0.82
Diamantina Health Partners: integrating leadership in research, research translation, education and clinical care. Med J Aust (2012) 0.81
Mutations in TAP genes are common in cervical carcinomas. Gynecol Oncol (2004) 0.80
Rapid kinetics to peak serum antibodies is achieved following influenza vaccination by dry-coated densely packed microprojections to skin. J Control Release (2011) 0.79
The early monocytic response to cytomegalovirus infection is MyD88 dependent but occurs independently of common inflammatory cytokine signals. Eur J Immunol (2013) 0.79
Nuclear RelB+ cells are found in normal lymphoid organs and in peripheral tissue in the context of inflammation, but not under normal resting conditions. Immunol Cell Biol (2002) 0.79
γδ T cells augment rejection of skin grafts by enhancing cross-priming of CD8 T cells to skin-derived antigen. J Invest Dermatol (2012) 0.79
Receptor for advanced glycation end products Glycine 82 Serine polymorphism and risk of cardiovascular events in rheumatoid arthritis. Arthritis Res Ther (2007) 0.79
Antigen-specific CD8 T cells can eliminate antigen-bearing keratinocytes with clonogenic potential via an IFN-gamma-dependent mechanism. J Invest Dermatol (2010) 0.79
Finding a vaccine for human papillomavirus. Lancet (2006) 0.78
Impact of sex steroid ablation on viral, tumour and vaccine responses in aged mice. PLoS One (2012) 0.78
Expression of papillomavirus L1 proteins regulated by authentic gene codon usage is favoured in G2/M-like cells in differentiating keratinocytes. Virology (2010) 0.78
Keratinocytes efficiently process endogenous antigens for cytotoxic T-cell mediated lysis. Exp Dermatol (2009) 0.78
Tumour susceptibility to innate and adaptive immunotherapy changes during tumour maturation. Immunol Cell Biol (2004) 0.78
Human growth hormone presented by K14hGH-transgenic skin grafts induces a strong immune response but no graft rejection. Immunol Cell Biol (2004) 0.77
Up-regulated expression of Sp1 protein coincident with a viral protein in human and mouse differentiating keratinocytes may act as a cell differentiation marker. Differentiation (2008) 0.77
Human papillomavirus 16 E7 protein inhibits interferon-γ-mediated enhancement of keratinocyte antigen processing and T-cell lysis. FEBS J (2011) 0.77
Interleukin-17A Promotes Arginase-1 Production and 2,4-Dinitrochlorobenzene-Induced Acute Hyperinflammation in Human Papillomavirus E7 Oncoprotein-Expressing Skin. J Innate Immun (2015) 0.76
Recombinant Wnt3a and Wnt5a elicit macrophage cytokine production and tolerization to microbial stimulation via Toll-like receptor 4. Eur J Immunol (2014) 0.76
A randomized trial of immunotherapy for persistent genital warts. Hum Vaccin Immunother (2012) 0.75
IL-1 signalling determines the fate of skin grafts expressing non-self protein in keratinocytes. Exp Dermatol (2010) 0.75
DNA Vaccine Encoding HPV16 Oncogenes E6 and E7 Induces Potent Cell-mediated and Humoral Immunity Which Protects in Tumor Challenge and Drives E7-expressing Skin Graft Rejection. J Immunother (2017) 0.75
Functional memory CD8+ T cells can be generated in vivo without evident T help. Vaccine (2004) 0.75
[Immunogenicity study of HPV 6b virus-like particles]. Zhonghua Yi Xue Za Zhi (2002) 0.75
The two faces of human papillomavirus. Gynecol Oncol (2010) 0.75